申请人:Yoshitomi Pharmaceutical Industries, Ltd.
公开号:US03935217A1
公开(公告)日:1976-01-27
Substituted pyrrolidinemethanols of the formula: ##SPC1## Wherein R.sup.1 and R.sup.2 are each H or C.sub.1.sub.-4 alkyl; R.sup.3, R.sup.4 and R.sup.5 are each H, halogen, C.sub.1.sub.-4 alkyl or C.sub.1.sub.-4 alkoxy, or R.sup.3 and R.sup.4 combinedly form methylenedioxy; and R is C.sub.1.sub.-10 alkyl or a group of the formula: ##SPC2## Where R.sup.6, R.sup.7 and R.sup.8 are each H, halogen, C.sub.1.sub.-4 alkyl or C.sub.1.sub.-4 alkoxy, or R.sup.6 and R.sup.7 combinedly form methylenedioxy; and pharmaceutically acceptable acid addition salts thereof are disclosed. They are useful as drugs for the treatment of diseases of the heart and circulation.
公式为:##SPC1## 其中 R.sup.1 和 R.sup.2 分别为 H 或 C.sub.1.sub.-4 烷基;R.sup.3、R.sup.4 和 R.sup.5 分别为 H、卤素、C.sub.1.sub.-4 烷基或 C.sub.1.sub.-4 烷氧基,或者 R.sup.3 和 R.sup.4 共同形成亚甲二氧基;R 为 C.sub.1.sub.-10 烷基或公式:##SPC2## 其中 R.sup.6、R.sup.7 和 R.sup.8 分别为 H、卤素、C.sub.1.sub.-4 烷基或 C.sub.1.sub.-4 烷氧基,或者 R.sup.6 和 R.sup.7 共同形成亚甲二氧基;以及其药学上可接受的酸盐。它们可用作治疗心脏和循环疾病的药物。